Literature DB >> 22025362

Susceptibility to winter vomiting disease: a sweet matter.

Gustaf E Rydell1, Elin Kindberg, Göran Larson, Lennart Svensson.   

Abstract

Norovirus, the cause of winter vomiting disease, has emerged in recent years to be a major cause of sporadic and epidemic gastroenteritis worldwide. The virus has been estimated to cause >200,000 deaths each year in developing countries. Although the virus is highly contagious, volunteer and field studies have shown that a subset of individuals appears resistant to infections. A single nucleotide mutation (G428A) in the fucosyltransferase gene (FUT2) on chromosome 19 provides strong protection from infection in 20% of the white population. Histo-blood group ABO(H) antigens with terminal fucose are believed to function as receptors for human norovirus in the gastrointestinal tract, but also negatively charged potential receptors have been identified. Norovirus infection is a unique example where a single nucleotide mutation in a fucosyltransferase gene plays a crucial role in susceptibility to one of the most common viral diseases. This review discusses the role of host genetics and carbohydrate structures in susceptibility to winter vomiting disease.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025362     DOI: 10.1002/rmv.704

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  22 in total

Review 1.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

Review 2.  Reciprocal interactions of the intestinal microbiota and immune system.

Authors:  Craig L Maynard; Charles O Elson; Robin D Hatton; Casey T Weaver
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

3.  Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner.

Authors:  Johan Nordgren; Sumit Sharma; Filemon Bucardo; Waqas Nasir; Gökçe Günaydın; Djeneba Ouermi; Leon W Nitiema; Sylvia Becker-Dreps; Jacques Simpore; Lennart Hammarström; Göran Larson; Lennart Svensson
Journal:  Clin Infect Dis       Date:  2014-08-05       Impact factor: 9.079

4.  Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades.

Authors:  Sumit Sharma; Beatrice Carlsson; Rita Czakó; Sirkka Vene; Mats Haglund; Johnny Ludvigsson; Göran Larson; Lennart Hammarström; Stanislav V Sosnovtsev; Robert L Atmar; Kim Y Green; Mary K Estes; Lennart Svensson
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

5.  Norovirus vaccine development: next steps.

Authors:  Robert L Atmar; Mary K Estes
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

Review 6.  Norovirus immunology: Of mice and mechanisms.

Authors:  Kira L Newman; Juan S Leon
Journal:  Eur J Immunol       Date:  2015-08-25       Impact factor: 5.532

Review 7.  Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.

Authors:  Eunüs S Ali; Harinda Rajapaksha; Jillian M Carr; Nikolai Petrovsky
Journal:  Antiviral Res       Date:  2016-07-13       Impact factor: 5.970

8.  Population-Level Human Secretor Status Is Associated With Genogroup 2 Type 4 Norovirus Predominance.

Authors:  Cory J Arrouzet; Karen Ellis; Anita Kambhampati; Yingxi Chen; Molly Steele; Ben Lopman
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

9.  Genetic Polymorphisms in the Host and COVID-19 Infection.

Authors:  Joris R Delanghe; Marc L De Buyzere; Marijn M Speeckaert
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Norovirus GII.4 virus-like particles recognize galactosylceramides in domains of planar supported lipid bilayers.

Authors:  Marta Bally; Gustaf E Rydell; Raphael Zahn; Waqas Nasir; Christian Eggeling; Michael E Breimer; Lennart Svensson; Fredrik Höök; Göran Larson
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-24       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.